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Determination of hexamethylene bisacetamide, an antineoplastic compound,
in mouse and human plasma by LC–MS/MS
Kerri M. Smith , Wannarasmi Ketchart , Xiang Zhou , Monica M. Montano , Yan Xu
Introduction
Hexamethylene bisacetamide (HMBA) is a hybrid bipolar
compound ﬁrst synthesized and characterized as an erythroid dif-
ferentiator for murine erythroleukemic cells (MELC) in 1976 [1].
Initially inspired by the structures and functions of DMSO and N-
methylacetamide, HMBA was used as the model differentiating
agent for a class compounds known as acetylated diamines. At a
concentration of 5mM, HMBA caused >99% of MELC in culture to
differentiate without cytotoxicity [1]. Furthermore, experimenta-
tion showed that HMBA also induced terminal differentiation in a
variety of leukemic cell lines [2,10]. Based on these ﬁndings, HMBA
was studied in several phase I and II clinical trials for the treatment
of myelodysplastic syndrome (MDS), acute myelogenous leukemia
(AML), general advanced cancer, and solid tumors [3–9]. However,
serious sideeffects ofHMBA, suchas thrombocytopenia, limited the
dose escalation and prevented sufﬁcient plasma concentrations to
be realized for its terminal differentiating potential.
Recent studies show that HMBA induced the expression of an
endogenous protein, hexamethylene bisacetamide inducible pro-
tein 1 (HEXIM1), which inhibits cell growth [11,12]. Increased
HEXIM1 expression in breast tumor and breast epithelial cells
resulted in a decrease of cell proliferation [12]. Additionally, not
only did HEXIM1 inhibit cell proliferation, it interacted with the
estrogen-receptor (ER)-gene transcription complex and prevented
mammary gland development in vivo [13]. Such properties indi-
cated a possible new role for HMBA in the treatment of breast
cancer. It has been proposed that HEXIM1 interferes with kinase
action at the coding region of ER-responsive genes preventing the
phosphorylation of RNA polymerase II (RNAP II) by the kinase com-
plex, positive transcriptional elongation factor b (P-TEFb) [13,14].
Phosphorylation of RNAP II by P-TEFb facilitates complete mRNA
elongation [15]. The prevention of this phosphorylation commits
the cell to the abortive phase of elongation, and halts transcription
[16].
To support studies of HMBA at lower doses as a potential ther-
apeutic agent for breast cancer, a sensitive analytical method is
required. Up to date, the published analyticalmethods for themea-
surement of HMBA in plasma and urine are LC–UV and GC-N/P
basedmethods, which have lower limits of quantitation (LLOQs) of
1.00g/mL and 2.00g/mL, respectively [17,18]. These and other
methods have been applied to several high-dose HMBA phase I
and II clinical trials [3–9,19,20], but the LLOQs of these methods
are not sufﬁcient for the measurement of HMBA in the majority
of biological samples for breast cancer study with concentrations
less than 1.00g/mL. This paper describes, for the ﬁrst time, the
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Fig. 1. Product ion spectra and structures of (A) HMBA and (B) 7MBA, the internal standard (IS).
development and validation of an LC–MS/MSmethod for the quan-
titative measurement of HMBA in both mouse and human plasma
with an LLOQ of 0.500ng/mL and a linear calibration range up to
100ng/mL. In thiswork, heptamethylenebisacetamide (7MBA)was
used as the internal standard. Both HMBA and 7MBA were recov-
ered from plasma matrices by a simple step of deproteinization
with acetonitrile. Separation of the analyte and internal standard
was achieved on a Waters Atlantis® T3 column using 15% ace-
tonitrile 85% 10mM ammonium acetate, pH 4.0 as mobile phase.
Quantitation was carried out by tandem mass spectrometry oper-
ated in the positive multiple-reaction-monitoring (MRM) mode.
Finally, the validated method was applied to the measurement of
HMBA concentrations in a preliminary mouse study.
Experimental
Chemicals and standard solutions
Ammonium acetate and hexamethylene bisacetamide (cata-
log no. 224235) were from Sigma–Aldrich (St. Louis, MO, USA).
HPLC-grade acetonitrile was from Pharmco-AAPER (Louisville,
KY, USA). HPLC-grade glacial acetic acid was from J.T. Baker
through VWR (West Chester, PA, USA). Sodium chloride,
sodium hydrogen phosphate, potassium dihydrogen phosphate,
sodium chloride, potassium chloride, 2,2,2-tribromoethanol,
and tert-amyl alcohol were from Fisher Scientiﬁc (Pittsburgh,
PA, USA). Heptamethylene bisacetamide (7MBA) was obtained
from the DTP Open Chemical Repository of the US National
Cancer Institute (http://dtp.cancer.gov) with assigned code
NSC36911. Six pooled blank human plasmas with speciﬁc lot
numbers (W06509203366, W06509105961, W069509203227,
W069509203370, W069509203365, and W069509203234) were
from Haemtech, Inc (Essex Junction, Vermont, USA), which were
donated by Dr. Michael Kalafatis at Cleveland State University. Six
pooled blank mouse plasmas (citrated) with speciﬁed lot num-
bers (09F21004, 11B21080, 11B21081, 11B21082, 11B21083, and
11B21084) were purchased from Lampire Biological Laboratories
(Pipersville, PA, USA). The Type 1 deionized water was obtained
from a Barnstead NANOpure® water puriﬁcation system (Thermo
Scientiﬁc, Waltham, MA, USA).
The mobile phase for liquid chromatographic separation was
prepared by mixing acetonitrile and 10mM ammonium acetate
(pH 4.0) at a ratio of 15:85 (v/v). The standard stock solutions of
HMBA and 7MBA were prepared in acetonitrile at a concentration
of 1mg/mL. The standard working solutions of HMBA at con-
centrations 50.0, 100, 150, 500, 1.00×103, 3.00×103, 5.00×103,
9.00×103, and 10.0×103 ng/mL were prepared by serial dilutions
of the standard stock solution of HMBAwith themobile phase. The
internal standard working solution of 100ng/mL was prepared by
two subsequent dilutions (1:100) of the standard stock solution of
7MBA in the mobile phase. The standard stock solutions were kept
in amber glass vials and stored at −20 ◦C.
Instrumentation
The liquid chromatography tandem mass spectrometry sys-
tem was comprised of a AB Sciex QTrap 5500 mass spectrometer
equipped with electrospray ionization (ESI) probe and syringe
pump (AB Sciex, Foster City, CA, USA), and a Shimadzu Promi-
nence UFLC systemwith binary pump and autosampler (Shimadzu,
Columbia, MD, USA). The systemwas connected using PEEK tubing
(1/16 in. o.d.×0.01 in. i.d.). Data was acquired and processed using
AB Sciex Analyst software (version 1.5.1).
Liquid chromatography
Analytical separation of HMBA and the IS was performed iso-
cratically at ambient temperature on a Waters Atlantis® T3 (3m,
120 A˚, 2.1mm×50mm) column (Waters, Milford, MA, USA) with
the mobile phase at the ﬂow rate of 0.150mL/min. The injection
volume of each sample was 5L. Prior to initial sample injection,
the column was equilibrated with the mobile phase at the above
ﬂow rate for a minimum of 15min.
Tandem mass spectrometry
The AB Sciex QTrap 5500 mass spectrometer was operated by
the positive electrospray ionization (ESI) mode using the following
instrument settings: CUR 34; CAD HIGH; IS 4500; TEM 550; GS1
38; GS2 32; DP 70; EP 10; CE 20; CXP 16. These settings were opti-
mized ﬁrst by direct infusion of 200ng/mL eachHMBA and the IS at
10L/min using the integrated syringe pump, then reﬁned by the
“Compound Optimization” feature of the Analyst software using
ﬂow injection analysis. HMBA and the IS were quantitated byMRM
mode using the following mass transitions: m/z 201.2→159.2 for
HMBAandm/z215.2→173.2 for 7MBA,withadwell timeof300ms
for each analyte.
Plasma calibrators and quality controls
Plasma calibrators and quality controls (QCs) were prepared
using the pooled blank human and mouse plasmas which con-
tained no detectable HMBA. Plasma calibrators were prepared by
addition of 10L of the mobile phase (for the blank of HMBA)
or each standard working solution of HMBA (50.0, 100, 500,
1.00×103, 5.00×103, and 10.0×103 ng/mL) to 990L of blank
pooled plasma for ﬁnal concentrations of 0.00, 0.500, 1.00, 5.00,
10.0, 50.0, and 100ng/mL each in a 1.5-mL microcentrifuge tube
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Fig. 2. Representative MRM  chromatograms of human plasma: (A) double blank and (B) 0.500 ng/mL HMBA (LLOQ), 20.0 ng/mL IS and mouse plasma; (C) double blank and
(D)  0.500 ng/mL HMBA, 20.0 ng/mL IS.
(VWR, West Chester, PA, USA). Plasma QCs were prepared by addi-
tion of 10 L of each standard working solution of HMBA (150,
3.00 × 103 and 9.00 × 103 ng/mL) to 990 L of blank pooled plasma
for ﬁnal concentrations of 1.50, 30.0, and 90.0 ng/mL each in a 1.5-
mL microcentrifuge tube. The plasma calibrators and QCs were
vortex-mixed for 30 s, and then stored overnight at −20 ◦C before
use.
Animal study
The  animal study protocol for this work was approved by
the Institutional Animal Care and Use Committee at Case West-
ern Reserve University. FVB mice from Jackson Laboratories (Bar
Harbor, ME,  USA) at 4–5 weeks of age were anesthetized using
Avertin (containing 1.3% tribromoethanol and 0.8% tert-amyl alco-
hol). HMBA (10 mg/kg) in saline (0.9% sodium chloride in water)
was then injected into the mammary tissue through the nipple. At
0 (pre-dose), 15, 30, 45, 60, 120, 240, 360, and 480 min, the mice
were ocularly bled and then sacriﬁced. Blood samples were col-
lected in sterile 1.5-mL microcentrifuge tubes and centrifuged at
3000 × g for 15 min. Mouse plasma samples were stored at −20 ◦C
until analysis. The developed LC/MS method was used to determine
the concentrations of HMBA in mouse plasma over the time course
of study.
Sample preparation
Plasma  calibrators and QCs, as well as mouse plasma samples
from FVB mice, were prepared as follows: samples were removed
from −20 ◦C freezer, and thawed to room temperature; for each
plasma sample, 25 L of plasma together with 5 L of the IS work-
ing  solution (100 ng/mL) or the mobile phase (for the blank of IS)
were added to 1.5-mL microcentrifuge tube, vortex-mixed for 30 s,
and kept at 4 ◦C for 30 min; the sample was then deproteinized with
100 L of HPLC-grade acetonitrile at a ratio of 3.3 to 1 by vortex-
mixing for 30 s; following centrifugation at 24,400 × g for 10 min,
the supernatant was  pipetted into a 1.5-mL microcentrifuge tube
and dried in a Savant DNA120 SpeedVac® concentrator (Thermo
Scientiﬁc, Asheville, NC, USA) at 43 ◦C for 30 min; ﬁnally, the resul-
tant residual was reconstituted in 25 L of the mobile phase for the
subsequent LC–MS/MS analysis.
Stability  studies
The  stability of HMBA in human and mouse plasma before
and after sample preparation, and through freeze-and-thaw cycles
were investigated at low, medium, and high QC concentrations.
These studies included QC samples kept on bench top at 22 ◦C for 0,
4, 8, and 24 h before sample preparation and analyses, QC  samples
kept in autosampler at 4 ◦C for 0, 4, 8, and 24 h after sample prepa-
ration and before LC–MS/MS analyses, and QC samples undergone
three freeze-and-thaw cycles where the samples were frozen at
−20 ◦C for at least 24 h and thawed at room temperature unassisted
3 times.
Results and discussion
Liquid  chromatography
Due  to its chemical structure, HMBA has a propensity to inter-
act with the particle substrate of the bonded phase resulting in
a tailing peak. Therefore, columns with endcapping (e.g., Waters
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Table 1
Recovery and matrix factor of HMBA in human and mouse plasma.
Nominal
[HMBA]
(ng/mL)
AHMBA/AIS in
plasma± SD
AHMBA/AIS in
matrix± SD
AHMBA/AIS in
mobile
phase± SD
Recoverya ± SD (%) MFb ± SD
Human
(n=3)
1.50 0.053 ± 0.001 0.055 ± 0.001 0.054 ± 0.001 96 ± 1 1.02 ± 0.03
30.0 1.04 ± 0.003 1.05 ± 0.01 1.05 ± 0.01 99 ± 1 1.00 ± 0.01
90.0 2.92 ± 0.01 3.01 ± 0.02 2.95 ± 0.02 98 ± 0.2 1.02 ± 0.01
Mouse
(n=3)
1.50 0.050 ± 0.001 0.049 ± 0.001 0.051 ± 0.002 102 ± 1 0.96 ± 0.03
30.0 0.94 ± 0.002 0.97 ± 0.04 0.96 ± 0.01 97 ± 4 1.01 ± 0.01
90.0 2.66 ± 0.004 2.68 ± 0.02 2.70 ± 0.03 99 ± 1 0.99 ± 0.01
a Recovery = [(mean area ratio of HMBA to IS in plasma sample)/(mean area ratio of HMBA to IS in plasma matrix after extraction)]×100%.
b Matrix factor (MF) = (mean area ratio of HMBA to IS in plasma matrix after extraction)/(mean area ratio of HMBA to IS in mobile phase).
XBridgeTM C8, Waters XTerra® C8, and Waters Atlantis® T3) were
considered for analytical separation. Among the columns tested,
Waters Atlantis® T3 (2.1mm×50mm, 3m) displayed not only
excellent retention times and reproducibility for the analytes, but
also symmetrical peak shapes without adding additional modiﬁers
to the mobile phase. Therefore, it was chosen for this work.
Mass spectrometric detection
Full-scan infusion analysis revealed [M+Na]+ as the predomi-
nant precursor ion in the aqueous solutions of both HMBA and the
IS (mass spectra not shown). The addition of an ammoniumsaltwas
effective to suppress the formation of [M+Na]+ andproduce [M+H]+
as the major precursor ions. After investigation with each ammo-
nium acetate and ammonium formate, it was determined that the
former resulted in greater detection signal; therefore, ammonium
acetate was added to the mobile phase in the subsequent studies.
Precursor ions [HMBA+H]+ at m/z 201.2 and [IS+H]+ at m/z 215.2
produced major product ions at m/z 159.2 and m/z 173.2 by break-
ing the amide bond (Fig. 1). Therefore, the mass transitions of m/z
201.2→159.2 forHMBAandm/z215.2→173.2 for the ISwereused
for the quantitation of HMBA by tandem mass spectrometry with
MRM mode.
Matrix interference and speciﬁcity
The use of Waters Atlantis® T3 (2.1mm×50mm) as analytical
column for separation and 35% methanol and 5mM ammonium
acetate (pH 6.8) as mobile phase was ﬁrst evaluated.While achiev-
ing excellent retention and separation for HMBA and the IS,
interferences were encountered in both plasma matrices, more
severely in mouse plasma (chromatograms not shown). This
unidentiﬁed endogenous compound co-eluted and produced a
common product ion of m/z 159.2 with HMBA in the tandem mass
spectrometer.
Table 2
Accuracy and precision of plasma calibrators (n=7) over three different days.
Nominal
[HMBA]
(ng/mL)
Accuracy (%E)a Precision (%CV)b
Human
plasma
Mouse
plasma
Human
plasma
Mouse
plasma
0.500 1 1 3 6
1.00 −1 3 2 2
5.00 −0.5 −3 3 2
10.0 2 −2 4 5
50.0 −3 2 2 3
100 1 −0.6 2 1
a %E= {(measured [HMBA]−nominal [HMBA])/nominal [HMBA]}×100%.
b %CV= (standard deviation/mean value)×100%.
Since choosing a different product ion for quantitation of
HMBA reduced the sensitivity of detection signiﬁcantly, other
approaches to minimize the interference were examined: (i) vari-
ous sample preparation methods, such as (a) protein precipitation
using various volume ratio of plasma to organic solvent(s) [i.e.,
plasma to acetonitrile ratio of 1:2, 1:3, 1:4, and 1:5 with and
without 0.1% formic acid or 0.1% ammonium hydroxide mod-
iﬁers; plasma to acetonitrile/methanol (75/25) ratio of 1:5, as
well as plasma to acetonitrile/ethanol (75/25) ratio of 1:5], (b)
liquid–liquid extraction with saturated ammonium sulfate and
15/85 isopropanol/ethyl acetate [21], and (c) denaturation of
plasma proteins by heating the sample at 100 ◦C for 5min prior
to centrifugation; (ii) separation by different types of column [e.g.,
Waters XBridgeTM C8 (2.1mm×50mm, 3m, 120 A˚) and Waters
XTerra® C8 (2.1mm×50mm, 3m, 120 A˚)]; and (iii) changing
mobile phase composition and/or pH.
All sample preparation methods tested yielded similar results
except liquid–liquid extraction with saturated ammonium sul-
fate and 15/85 isopropanol/ethyl acetate, which worsened the
interference. Among the columns examined, the Waters Atlantis®
T3 (2.1mm×50mm) column displayed the best chromatographic
performance. The most satisfactory results were obtained by
changing the mobile phase organic composition and pH (i.e., 15%
acetonitrile, 85% 10mM ammonium acetate at pH 4.0) for both
human and mouse plasma.
Finally, the optimal separation of HMBA and the ISwas achieved
on a Waters Atlantis® T3 (2.1mm×50mm) column at 2.2 and
3.7min by a mobile phase containing 15% acetonitrile, 85% 10mM
ammonium acetate at pH 4.0 using 3.3 volumes of acetonitrile
for deproteinization. Under these conditions, the previously co-
eluted interference was completely resolved from human plasma
(Fig. 2A and B). Even though the interfering compound in mouse
plasma was not completely removed (Fig. 2C, top trace), it had
been reduced to a minimum that was insigniﬁcant for the anal-
ysis. The peak area of the interference in mouse plasma was about
8% of the LLOQ for HMBA by the LC–MS/MS method (Fig. 2C and
D), an acceptable level by the industry [22]. The speciﬁcity of the
LC–MS/MSmethodwas further demonstrated bymeasuringHMBA
at the LLOQ (0.500ng/mL) of the method from six lots of human
plasma samples and six lots of mouse plasma samples (see Section
3.4.2).
Method validation
The method was validated following the guidelines brought
forth by the FDA’s Bioanalytical Method Validation Guidance for
Industry [22,23].
Recovery and matrix factor
Recovery was calculated by comparing the mean-peak-area
ratios of HMBA to the IS of corresponding QC samples prepared
by spiking the analytes to plasma matrix before and after plasma
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Table  3
HMBA at LLOQ in different lots of human and mouse plasmas.
Lot A Lot B Lot C Lot D Lot E Lot F
Nominal  [HMBA] (ng/mL) 0.500 0.500 0.500 0.500 0.500 0.500
Human
(n = 5)
Mean 0.525 0.502 0.491 0.463 0.461 0.472
Standard  Dev (SD) 0.010 0.004 0.014 0.002 0.004 0.006
Accuracy  (%E) 5 0.3 −2 −7 −8 −6
Precision  (%CV) 2 1 3 0.5 1 1
Mouse
(n = 5)
Mean 0.528 0.486 0.498 0.489 0.475 0.497
Standard  Dev (SD) 0.013 0.043 0.031 0.035 0.010 0.028
Accuracy  (%E) 6 −3 −0.3 −2 −5 −1
Precision  (%CV) 3 9 6 7 2 6
Each datum point calculated by ﬁve parallel measurements from ﬁve identical QCs.
deproteinization. Matrix factor was calculated by comparing the
mean-peak-area ratios of HMBA to the IS in the QC samples pre-
pared by spiking the analytes after plasma deproteinization to
those prepared in the mobile phase. For these studies, triplicate
measurements were performed for all low, medium, and high QC
concentrations.
Table 1 shows that the recoveries of HMBA were consistent and
between 96% and 98% in human plasma, and 97% and 102% in mouse
plasma over the three concentrations examined. Deproteinization
by 3.3 volumes of acetonitrile was sufﬁcient to recover HMBA from
the matrices.
Matrix factor is a measure of sample matrix effect (either sup-
pression or enhancement) on analytical signal of HMBA. In this
work, matrix factor for human and mouse plasma ranged 0.96–1.02
(Table 1), which indicated that the plasma matrix effect was in the
magnitude of −4% to 2% (<±15%). Hence, the plasma matrix sup-
pression or enhancement of the analytical signals was  no signiﬁcant
and could be neglected without further correction.
Calibration curve and lower limit of quantitation
The linear calibration ranges of 0.500–100 ng/mL were estab-
lished for HMBA in both human and mouse plasma with internal
standard using six non-zero calibrators, a single-blank (IS only), and
a double-blank. The calibration equations derived from seven indi-
vidual calibration curves on three different days with 1/x weighting
were y = 0.0287(±0.0046)x + 0.084(±0.0043), r2 = 1.00 for human
plasma, and y = 0.0294(±0.0030)x + 0.0118(±0.0057), r2 = 0.999 for
mouse plasma. The accuracy and precision of each individual cal-
ibrator as summarized in Table 2, were ≤±3% and ≤6% in both
human and mouse plasma.
The LLOQ of the method was deﬁned by the lowest calibrator
(0.500 ng/mL) of the calibration curve, which was conﬁrmed by
measuring HMBA from six lots of human plasma samples and six
lots of mouse plasma samples. The precision and accuracy of each
lot of plasma at LLOQ were calculated based on ﬁve separate sam-
ples with one injection per sample. The data are summarized in
Table 3. The accuracy and the precision of the method at the LLOQ
were  ≤±8% and ≤3% in human plasma, and ≤±6% and ≤9% in mouse
plasma, respectively.
Precision, accuracy, and dilution studies
Inter-assay precision and accuracy were assessed by ﬁve paral-
lel injections from ﬁve identical QC samples at each concentration
over three separate days of analysis. Intra-assay precision and accu-
racy were assessed by ﬁve parallel injections from ﬁve identical QC
samples at each concentration. Accuracy was  expressed as percent
relative error (%E), and precision was determined as percent stan-
dard deviation or coefﬁcient of variation (%CV). As shown in Table 4,
the intra- and inter assay accuracy and precision were ≤±9% and
≤10% for both human and mouse plasmas.
Since the upper limits of the linear calibrations curve were
100 ng/mL, sample concentrations beyond these concentrations
were subject to dilution studies. In this work, dilution effect was
assessed by 1:100 dilution of plasma QCs at the concentrations of
150, 3.00 × 103, and 9.00 × 103 ng/mL by the pooled blank plasma,
with the data summarized in Table 5. As shown in the table, the
dilution study had an accuracy of ≤±10% and precision of ≤3% over
the concentration range studied. These results indicated that dilu-
tion of plasma samples which had concentrations beyond the upper
limit of the calibration curve would not produce signiﬁcant error
in the measurement of actual HMBA concentrations.
Stability
The stability of HMBA was determined by comparing the mean-
peak-area ratios of HMBA to the IS in the QC samples to those of
freshly prepared QCs, expressed in terms of recovery. As shown
in Table 6, the recoveries of QC samples were 98–106%, 97–107%,
and 91–103% for the bench top, the autosampler, and the freeze-
and-thaw studies, respectively. These studies indicated that there
was  no signiﬁcant deviation in the quantitation of HMBA under the
experimental conditions.
Table 4
Intra-  and inter-accuracy and precision of HMBA in plasma.
Intra-run Inter-run
Nominal
[HMBA]
(ng/mL)
Measured
[HMBA]a ± SD
(ng/mL)
Accuracy
(%E)
Precision
(%CV)
Measured
[HMBA]b ± SD
(ng/mL)
Accuracy
(%E)
Precision
(%CV)
Human 1.50  1.59 ± 0.03 6 2 1.46 ± 0.14 −3 10
30.0 31.2 ± 0.6 4 2 29.5 ± 1.6 −2 6
90.0 87 ± 3 −3 3 82 ± 4 −9 5
Mouse 1.50  1.60 ± 0.02 7 1 1.44 ± 0.14 −4 10
30.0 31.6 ± 0.8 5 2 32.1 ± 1.1 7 3
90.0 94 ± 1 4 1 94 ± 4 4 4
a Each datum point calculated by ﬁve parallel measurements from ﬁve identical QCs.
b Each datum point calculated by ﬁve parallel measurements from ﬁve identical QCs of three different days.
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Table 5
Dilution studies.
Initial [HMBA]
(ng/mL)
Dilution
factor
Nominal
[HMBA]
(ng/mL)
Measured
[HMBA]± SD
(ng/mL)
Accuracy
(%E)
Precision
(%CV)
Actual [HMBA]
(ng/mL)
Human
(n=3)
150 100 1.50 1.51 ± 0.05 1 3 151
3.00×103 100 30.0 29.2 ± 0.2 −3 1 2.92×103
9.00×103 100 90.0 92.9 ± 1.0 3 1 9.29×103
Mouse
(n=3)
150 100 1.50 1.52 ± 0.04 1 3 152
3.00×103 100 30.0 31.9 ± 0.8 6 2 3.19×103
9.00×103 100 90.0 98.9 ± 1.6 10 2 9.89×103
Table 6
Stability of HMBA in plasma samples.
Nominal
[HMBA]
(ng/mL)
4h 8h 24h 3 Freeze–thaw
cycles
Recovery± SD (%) Recovery± SD (%) Recovery± SD (%) Recovery± SD (%)
Bench-top stability (before
deproteinization)
(n=3)
Human 1.50 101 ± 5 100 ± 5 101 ± 7 91 ± 1
30.0 106±4 104 ± 4 105 ± 2 100 ± 2
90.0 105 ± 3 104 ± 1 104 ± 1 103 ± 1
Mouse 1.50 102 ± 1 102 ± 2 103 ± 2 103 ± 2
30.0 99 ± 1 98 ± 2 99 ± 1 97 ± 0.4
90.0 100 ± 4 102 ± 4 101 ± 3 101 ± 4
Autosampler stability (after
deproteinization)
(n=3)
Human 1.50 102 ± 2 100 ± 4 107 ± 4
30.0 102 ± 2 100 ± 3 101 ± 3
90.0 104 ± 0.1 103 ± 2 103 ± 0.3
Mouse 1.50 100 ± 3 101 ± 1 98 ± 1
30.0 100 ± 1 103 ± 1 97 ± 1
90.0 101 ± 5 103 ± 2 97 ± 3
Fig. 3. Mean concentrations of HMBA in mice over time.
Application to animal study
The validated LC–MS/MS method was applied to the measure-
ment of HMBA in FVB mice. In this work, mouse plasma samples
collected by the procedure described in Section 2.6 together with
eight calibrators (i.e., one single-blank, one double-blank and six
nonzero) and a set of QCs at low-, mid- and high-concentrations
(i.e., 1.50, 30.0, 90.0ng/mL) were thawed at room temperature.
These samples were prepared by the procedures described in Sec-
tion 2.7, and analyzed by the validated method. The samples of
concentrations beyond the upper limit of calibration curve (i.e.,
100ng/mL) were re-run by 1:100 dilution using the pooled blank
mouse plasma together with the dilution QC at the concentration
of 9.00×103 ng/mL. Fig. 3 shows the HMBA concentration–time
proﬁle in FVB mice after a nipple injection of 10mg/kg. Each
datum point was based on duplicate measurement of a blood sam-
ple from an FVB mouse. Although a higher dose of HMBA was
used in this preliminary study, the concentration–time proﬁle of
HMBA demonstrated not only the applicability of themethod in its
intended sample matrix, but also its feasibility for a wide concen-
tration range of HMBA in plasma (from sub ng/mL to high g/mL).
This method will be used in the future delayed release dosing reg-
imen which should have much lower plasma HMBA concentration
proﬁle.
Conclusions
This work detailed the development and validation of a
LC–MS/MS method for the quantitation of HMBA in human and
mouse plasma. Themethod used a simple deproteinization step for
sample preparation, and a reversed-phase chromatographic col-
umn for analyte separation. It has a linear calibration range of
0.500–100ng/mLandstability for routine analysis. Themethodwas
successfully applied to themeasurement ofHMBA inmouseplasma
samples. It may be useful for the toxicokinetic study of HMBA in
mice as well as pharmacokinetic study in humans.
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